Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 9Neoplasms 7Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Colorectal Neoplasms 5Lymphoma 4Liver Neoplasms 4Lung Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mesothelioma 2Locally Advanced Rectal Cancer 2Hematologic Diseases 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Adenocarcinoma 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Solid Tumor, Adult 1

Interventions

pembrolizumab 124Cisplatin 27lenvatinib 24Carboplatin 24Paclitaxel 19Docetaxel 16Fluorouracil 13Capecitabine 11Pemetrexed 10Gemcitabine 10Saline Solution 8Oxaliplatin 8epacadostat 6Leucovorin 5Irinotecan 5Cetuximab 5olaparib 4Bevacizumab 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4trifluridine tipiracil drug combination 3regorafenib 3enzalutamide 3durvalumab 3Nivolumab 3Etoposide 3trametinib 2etoposide phosphate 2dabrafenib 2Tretinoin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Parkinson Disease 4, Autosomal Dominant Lewy Body × spartalizumab × Clear all
NCT02403193 2022-01-12

AdenONCO

Palobiofarma SL

Phase 1 Completed
92 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡